Search results for: Market Access

OHE This Week: BioWales 2013, UK Medicines Market and EQ-5D in Asia

18 March 2013

…presentation on the economics of the market for medicines at City College in London. 21/22 March: Nancy Devlin will be in Singapore with EuroQol colleagues. Until 12 April, OHE is…

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

1 July 2018

…dynamic inefficiency or a suboptimal (too low) investment in innovation. However, too much IP protection might grant the originator market power for an excessive period. Such market power enables prices…

Health Care without Frontiers?

1 December 2000

…on how an internal EU market in health care delivery is likely to develop in the future. The purpose of this paper is to set out the background to the…

Private Health Care

1 July 1985

…coherent market boundaries. In many cases, these coincide roughly with NHS administrative divisions.… This survey covers all major areas of health care in Britain and describes the activity of the…

Consumer Movement, Health, and the Pharmaceutical Industry

1 January 1983

…an equivalent freedom to compete to meet the market’s demands. The suggested advantages of this type of social system are two-fold. First, where free competition is working in a fair,…

Economics of Innovation

…to medical innovation?   What role does market competition play in promoting investment in R&D and maximising access to medical innovation? Key objective for this research theme: Promoting innovation in health…

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

30 June 2022

…and Health Technology Assessment (HTA) initiatives, such as PRIME and the Joint Clinical Assessment (JCA); continuing to build Patient Groups capabilities to facilitate technical discussions on market access topics. In…

Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds

3 March 2020

…annual treatment costs exceeding a certain amount will be set using market size and the pharmacoeconomic factors of treatment cost, incremental cost and incremental QALYs, valued using a CET of…

OHE in the Spotlight: Summer 2011

22 September 2011

…in emerging market health care systems.  With Lou Garrison of University of Washington, Adrian Towse presented at the Industry HTA Learnings session on progress on the HTA emerging markets project…